Squarepoint Ops LLC Has $608,000 Holdings in Cytokinetics, Incorporated $CYTK

Squarepoint Ops LLC trimmed its position in Cytokinetics, Incorporated (NASDAQ:CYTK) by 82.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,398 shares of the biopharmaceutical company’s stock after selling 85,480 shares during the quarter. Squarepoint Ops LLC’s holdings in Cytokinetics were worth $608,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. HighTower Advisors LLC lifted its position in shares of Cytokinetics by 21.8% in the 1st quarter. HighTower Advisors LLC now owns 11,352 shares of the biopharmaceutical company’s stock valued at $456,000 after acquiring an additional 2,029 shares in the last quarter. CW Advisors LLC acquired a new stake in Cytokinetics during the 1st quarter valued at $1,125,000. AlphaQuest LLC lifted its holdings in shares of Cytokinetics by 485.4% in the first quarter. AlphaQuest LLC now owns 6,650 shares of the biopharmaceutical company’s stock valued at $267,000 after purchasing an additional 5,514 shares in the last quarter. Comerica Bank boosted its position in shares of Cytokinetics by 3.2% in the first quarter. Comerica Bank now owns 243,109 shares of the biopharmaceutical company’s stock worth $9,771,000 after buying an additional 7,645 shares during the period. Finally, Gabelli Funds LLC boosted its position in shares of Cytokinetics by 30.0% in the first quarter. Gabelli Funds LLC now owns 6,500 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 1,500 shares during the period.

Cytokinetics Stock Performance

NASDAQ:CYTK opened at $63.29 on Wednesday. The company has a market capitalization of $7.74 billion, a P/E ratio of -10.06 and a beta of 0.58. The stock’s 50 day moving average price is $62.87 and its 200 day moving average price is $49.10. Cytokinetics, Incorporated has a 52 week low of $29.31 and a 52 week high of $70.98.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.59) by $0.05. The business had revenue of $1.94 million during the quarter, compared to the consensus estimate of $6.05 million. The business’s revenue was up 318.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.36) earnings per share. As a group, sell-side analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: FDA approved Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy, turning Cytokinetics into a commercial-stage cardiology biotech and opening a new revenue runway — a primary driver behind the rally. Article Title
• Positive Sentiment: Multiple brokers lifted price targets and reiterated buy/outperform views (Barclays, Morgan Stanley, BofA, Needham, Citizens/JMP), signaling stronger analyst conviction on commercial prospects and supporting upside. Article Title
• Positive Sentiment: Unusually heavy call-option buying (about 5,619 calls, ~103% above typical daily volume) suggests traders are positioning for additional upside or near-term bullish moves. (Options volume report)
• Positive Sentiment: Analyst commentary highlights practical label advantages for MYQORZO vs. the incumbent (flexible dosing), and management targets substantial market share gains — commentary that supports a multi-quarter adoption story. Article Title
• Neutral Sentiment: Citizens maintained its Market Outperform rating on CYTK, which is supportive but not a new endorsement. Article Title
• Negative Sentiment: Insider selling: director Wendell Wierenga sold 20,000 shares at an average $66.14 (Dec. 22), trimming his stake ~38% — a potential short-term headwind or cautionary signal for some investors. SEC Filing

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. HC Wainwright upped their price target on Cytokinetics from $120.00 to $136.00 and gave the company a “buy” rating in a research report on Monday. The Goldman Sachs Group set a $95.00 target price on Cytokinetics and gave the company a “buy” rating in a report on Thursday, December 18th. Citigroup restated a “market outperform” rating on shares of Cytokinetics in a report on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cytokinetics in a research report on Tuesday, October 21st. Finally, Royal Bank Of Canada increased their target price on shares of Cytokinetics from $87.00 to $95.00 and gave the stock an “outperform” rating in a research report on Monday. Fifteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $83.61.

Insider Transactions at Cytokinetics

In related news, Director Wendell Wierenga sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $66.14, for a total value of $1,322,800.00. Following the transaction, the director directly owned 32,444 shares of the company’s stock, valued at approximately $2,145,846.16. This trade represents a 38.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Md Kaye sold 28,064 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $66.72, for a total value of $1,872,430.08. Following the completion of the sale, the director owned 9,977 shares of the company’s stock, valued at approximately $665,665.44. This trade represents a 73.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 168,494 shares of company stock valued at $10,811,018 in the last three months. 3.40% of the stock is currently owned by company insiders.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.